{"entity":{"id":"philippe-moreau","kind":"person","name":"Philippe Moreau","aka":[],"tldr":"Led MajesTEC-1 and CASSIOPEIA, bringing the first bispecific antibody and daratumumab quadruplets to myeloma.","summary":"Philippe Moreau (Nantes) was principal investigator of MajesTEC-1, the pivotal trial of teclistamab, the first BCMA-directed bispecific antibody approved for relapsed myeloma, and of CASSIOPEIA, which established daratumumab with bortezomib-thalidomide-dexamethasone in transplant-eligible patients. He has led IFM trials for two decades including the IFM 2009 transplant study and is a past chair of the IFM.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Moreau%20P%5BAuthor%5D%20myeloma%20teclistamab%20OR%20daratumumab"}],"tags":["myeloma","bispecific","trialist"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["bispecific-antibody","t-cell-engager"],"targets":["bcma","cd38","cd3"],"drugs":["teclistamab"],"companies":[],"institutions":["chu-nantes"],"pathways":[],"terms":[],"trials":["majestec-1","majestec-3"],"people":[],"bottlenecks":[],"keyPapers":["paper-majestec-1-teclistamab-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Head of the Hematology Department, University Hospital Hôtel-Dieu, Nantes","institutionId":"chu-nantes","specialisms":["Multiple myeloma","Bispecific antibodies","Daratumumab combinations","Transplant-eligible myeloma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Moreau%20P%5BAuthor%5D%20myeloma%20teclistamab%20OR%20daratumumab"}],"papers":[{"title":"Teclistamab in relapsed or refractory multiple myeloma (MajesTEC-1)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2203478"},{"title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA)","journal":"Lancet","year":2019,"doi":"10.1016/S0140-6736(19)31240-1"}]},"route":"/people/philippe-moreau/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"},{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"},{"id":"cd38","kind":"target","name":"CD38","route":"/targets/cd38/"}],"drug":[{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/"}],"institution":[{"id":"chu-nantes","kind":"institution","name":"Nantes University Hospital (CHU de Nantes)","route":"/institutions/chu-nantes/"}],"trial":[{"id":"cassiopeia","kind":"trial","name":"CASSIOPEIA","route":"/trials/cassiopeia/"},{"id":"majestec-1","kind":"trial","name":"MajesTEC-1","route":"/trials/majestec-1/"},{"id":"majestec-3","kind":"trial","name":"MajesTEC-3","route":"/trials/majestec-3/"}],"paper":[{"id":"paper-majestec-1-teclistamab-nejm-2022","kind":"paper","name":"MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma","route":"/key-papers/paper-majestec-1-teclistamab-nejm-2022/"}]}}